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and men with diabetes-related comorbidities/complications by
13% and 5% compared to IDDM without diabetes reated
comorbidities/complications. The probability of working for
women and men with NIDDM also were 7% and 2% less than
women and men without this disorder. Similarly, these proba-
bilities were even smaller for women and men with NIDDM
related comorbidities/complications by 2% compared with
NIDDM without diabetes reated comorbidities/complications
(all at p-values <0.05). The predicted weekly work hours for
women and men without diabetes were 29 and 41 hours, with
IDDM were 18 and 30, with IDDM and comorbidities/compli-
cations were 13 and 23, with NIDDM were 21 and 35 hours
and ﬁnally with NIDDM and related comorbidities/complica-
tions were 17 and 30, respectively. CONCLUSIONS: The effect
of diabetes and its related comorbidities especially for men with
NIDDM and related comorbidities/complications on the proba-
bility of unemployment and predicted weekly work hours in
Canada are substantial. The results of this study have implica-
tions for cost-effectiveness of diabetes control and may facilitate
studies of the health burden of diabetes for the prevention and
treatment of diabetes and thus increase the labor productivity.
DB3
DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS
LEAD TO IMPROVED LONG TERM COST EFFECTIVENESS OF
BIPHASIC INSULIN ASPART 30/70 VERSUS BIPHASIC HUMAN
INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN DANISH,
FINNISH, GERMAN, NORWEGIAN, SPANISH, SWEDISH,AND
UK SETTINGS
Lammert M1, Palmer AJ2, Roze S2, Minshall ME3,Valentine WJ2
1Novo Nordisk A/S, Bagsvaerd, Denmark; 2CORE Center for
Outcomes Research, Binningen/Basel, Switzerland; 3CORE-USA,
Fishers, IN, USA
OBJECTIVES: A 24-month randomised, open-label parallel
group study in type 2 diabetes patients compared the safety and
efﬁcacy of biphasic insulin aspart (BIAsp30/70) and biphasic
human insulin (BHI30/70) injected twice daily before meals.
Major hypoglycaemic episodes were reduced with BIAsp30/70
(annual rate 4.1%) versus BHI30/70 (annual rate 15.5%) and
were signiﬁcantly lower in the second study year (p = 0.04). Gly-
caemic control did not differ between groups. A peer-reviewed,
validated model projected the impact of the different rates of
major hypoglycaemia events on long-term health economic out-
comes in multinational settings. METHODS: The CORE Dia-
betes model employs standard Markov/Monte Carlo simulation
techniques to describe long-term incidence and progression of
diabetes-related complications. Transition probabilities were
derived from major diabetes studies. The clinical effects of the
comparators were derived from the trial described. The analysis
was performed in multinational settings using published country-
speciﬁc costs, health care resource utilization, clinical data, and
recommended discount rates. A lifetime horizon and payer per-
spective was taken. Only direct costs were considered. Sensitiv-
ity analyses was performed. RESULTS: Discounted
quality-adjusted life years (QALY) were improved by 0.15–0.22
years with BIAsp30/70 versus BHI30/70 depending on country
speciﬁc discount rates. Increases in lifetime costs were seen with
BIAsp30/70 in all settings. Costs per QALY were DKK61,922,
9784€, 12,840€, NOK38,911€, 14,068€, SEK76,495€, and
£6,585 in the Danish, Finnish, German, Norwegian, Spanish,
Swedish, and UK setting respectively. Results were most sensi-
tive to assumptions regarding major hypoglycaemia rates, mor-
tality following major hypoglycemic events, HbA1c changes and
to the relative costs of BIAsp30/70 versus BHI30/70. CON-
CLUSIONS: Treatment with BIAsp30/70 was projected to result
in additional QALYS and reduced health care costs associated
with major hypoglycaemic events versus treatment with
BHI30/70. The higher acquisition costs of BIAsp30/70 led to
increased overall costs, but the incremental cost/QALY fell
within the range generally considered to be cost-effective in each
country.
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PROOF OF CONCEPT OF A WIRELESS APPROACH FOR
ENABLING COMMUNICATIONS BETWEEN GERMAN
PHYSICIANS AND THEIR PATIENTS WITH TYPE 2 DIABETES
TREATED WITH NATEGLINIDE
Netherton DR1, LeVine P2
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OBJECTIVE: We report on the results of proof-of-concept study
designed to encourage patient adherence to treatment guidelines
and allow German physicians treating patients with Type-2 dia-
betes with nateglinide to gain patient feedback using an entirely
wireless design. Subject Sample: 60 patients and 5 physicians
agreed to participate in the study. METHODS: Using mobile
communications devices, patients reported on their medication-
taking experience and clinical values, including blood glucose
levels, according to a clinical protocol have ﬁve (5) patient
reporting events during the study period of 14 days. This infor-
mation was then delivered via dedicated web technology to treat-
ing physicians. RESULTS: Participating physicians enrolled an
average of seven patients in the study. Each physician visited the
website an average of 40 times. Twenty-one percent of these
visits involved the physician reviewing individual patient
responses. Sixty percent of physicians agreed that their under-
standing of the medication and of the condition was improved
by their participation in the study. Sixty-ﬁve percent of patients
reported believing that the wireless handset device was easy to
use, and 71% noted that the screen of the device was acceptable
for reading, navigating and entering information about their con-
dition. CONCLUSIONS: In a small, proof-of-concept study
designed to assess the viability of entirely automated communi-
cations among physicians and patients regarding treatment and
clinical endpoints in Type-2 diabetes, both physicians and
patients were able to use the system without signiﬁcant difﬁculty
and reported favorable experiences with the approach.
UTILITIES & COSTS
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HEALTH ECONOMIC COMPARISON OF CONTINUOUS
SUBCUTANEOUS INSULIN INFUSION WITH MULTIPLE DAILY
INJECTION FOR THE TREATMENT OF TYPE 1 DIABETES IN
THE UK
Zakrzewska K1, Roze S2,Valentine WJ2, Palmer AJ2
1Medtronic AG,Tolochenaz, Switzerland; 2CORE Center for
Outcomes Research, Binningen/Basel, Switzerland
OBJECTIVES: The aim of this study was to project the long term
costs and outcomes of continuous subcutaneous insulin infusion
(CSII) compared with multiple daily injection (MDI) in patients
with type 1 diabetes (T1D) in the UK. METHODS: The CORE
Diabetes Model is a peer-reviewed, validated model that employs
standard Markov/Monte Carlo simulation techniques to describe
the long term incidence and progression of diabetes-related com-
plications. Baseline cohort characteristics were taken from pub-
lished studies of T1D in the UK (mean age 26 years, duration of
diabetes 12 years, 54% male, 90% Caucasian, mean HbA1c
8.68%). Transition probabilities were derived from major dia-
betes clinical studies. Effects associated with CSII and MDI deliv-
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ery systems were taken from a recent meta-analysis. Published
UK costs for 2003, health care resource utilization and clinical
data, and recommended discount rates were used (3.5% per
annum on costs and outcomes). A lifetime horizon and third
party payer perspective was taken. Only direct costs were 
considered. Extensive sensitivity analyses were performed.
RESULTS: Treatment with CSII was associated with an improve-
ment in life expectancy (LE) of 0.72 years compared to MDI
(mean LE 17.37 ± 6.81 versus 16.66 ± 6.62 years). Quality
adjusted life expectancy (QALE) improved by 0.59 years with
CSII versus MDI (mean QALE 10.23 ± 3.89 versus 9.64 ± 3.69
years). Mean direct lifetime costs were £19,413 more expensive
with CSII treatment versus MDI (£81,115 versus £57,015). This
produced an incremental cost effectiveness ratio of £32,753 per
quality adjust life year saved with CSII compared to MDI. The
main difference between the two arms was in medication costs.
Sensitivity analysis showed the results were robust under a range
of assumptions. CONCLUSIONS: Improvements in glycemic
control associated with CSII versus MDI lead to improvements
in LE and QALE due reduced incidence of diabetes-related com-
plications. CSII is cost effective compared to MDI according to
accepted international thresholds.
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PATIENTS’ PREFERENCES FOR INGUINAL HERNIA REPAIR
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OBJECTIVE: Inguinal hernia repair is a common surgical pro-
cedure. Available evidence suggests that there are advantages and
disadvantages to open and laparoscopic repair. The value that
patients attach to the proﬁle of outcomes is uncertain. The objec-
tive is to elicit patients’ values for the proﬁle of outcomes for
each surgical technique. METHODS: A postal discrete choice
survey was developed containing 7 attributes with 3 levels each,
identiﬁed from the literature, expert opinion and a pilot study.
A fractional factorial design reduced the number of scenarios to
18, using SPEED. The scenarios were systematically paired into
9 binary choices to derive an efﬁcient design (orthogonality, level
balance, utility balance and minimal overlap). Respondents were
asked to choose operation A or B in each pair-wise choice and
indicate the strength of their preference. Dominance and consis-
tency tests, and a ranking exercise were also included. Results
were analysed in STATA using a random effects probit model.
The study sample was 50 post-operative patients (25 laparo-
scopic, 25 open) and 50 patients waiting for an inguinal hernia
repair at one hospital. RESULTS: In total, 63% of patients
returned the questionnaire, (18 post-laparoscopic, 10 post-open
and 35 waiting). The mean age of respondents was 53 years
(range: 25 :87), 58% were retired. Initial analysis of complete
responses, based on the sign and signiﬁcance of the regression
coefﬁcients, indicated patients prefer operations with: 1 over-
night stay (b = 0.446) to those with 0 or 2+ nights; least risk of
operative-complications (b = -0.195); longer return to usual
activities (b = 0.049); least post-operative pain (b = -0.042);
lowest chance of recurrence (b = -0.033); complications after the
operation (b = 0.031); and, least long-term pain (b = -0.009).
Overall the signs on the coefﬁcients were consistent with a priori
expectations. All attributes were statistically signiﬁcant (p <
0.01). CONCLUSION: Patients value those attributes describ-
ing immediate care/outcome more than those that affect long-
term outcome. 
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A FIVE-LEVEL VERSION OF EQ-5D
Kind P1, Macran S2
1Outcomes Research Group,York, UK; 2University of York,York, UK
OBJECTIVES: EQ-5D deﬁnes health in terms of 5 dimensions
each divided into 3 levels, forming a classiﬁcation of 245 states.
The ﬁrst level within each dimension corresponds to “no
problem” and it has been suggested that the classiﬁcation lacks
scope for sensitivity. A 5-level descriptive classiﬁcation offers
advantages with smaller step sizes than is presently the case,
leading to reduced ceiling effects. This paper reports on a study
that compares self-rated health status in a patient survey using
a modiﬁed 5-level descriptive classiﬁcation alongside the con-
ventional 3-level EQ-5D. METHODS: EQ-5D was modiﬁed by
inserting an intermediate level between the existing levels 1&2
and 2&3. No text labels were provided for these levels 2 and 4
of the modiﬁed version. A questionnaire containing both 3-level
and 5-level responses systems was constructed. The order of pre-
sentation was varied with 50% presenting the standard EQ-5D
format ﬁrst; in the remainder the 5-level version was presented
ﬁrst. Questionnaires were mailed out to over 2000 individuals
selected from the national electoral register. RESULTS: Data
from 950 respondents were available for analysis (n = 478 for
3-5 version and 472 for the 5-3 version respectively). 64% of
respondents were indifferent when asked which version they pre-
ferred. Of the remainder 65% preferred the 5-level version.
Response errors were deﬁned as a difference in response of more
than 1 level between the 2 versions and these were generally less
than 1%. There was a smaller ceiling effect and only 39% of
respondents reported no problems on the 5-level version. The
corresponding rate for the 3-level version was 50%. CONCLU-
SIONS: A 5-level response system for EQ-5D is feasible. The
revised version produced a wider distribution of reported prob-
lems with less compacting towards level 1. Backwards com-
patability ensures that existing valuation sets can be used with
both 3- and 5-level systems.
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OBJECTIVES: The Barthel Index (BI) is a validated activities of
daily living (ADL) scale covering bowel and bladder functioning,
grooming, toileting, feeding, transfers, mobility, dressing, stairs,
and bathing. Scores range from 0–100 (0 = total dependence,
100 = complete independence). Mathematically, the BI allows for
5,146 possible proﬁles; however, many do not occur clinically
due to hierarchical conservation of function. Published informa-
tion on clinical representation of BI proﬁles and diversity within
scores is scarce. We explored those issues and their clinical and
economic implications. METHODS: A BI proﬁle was deﬁned as
the score set for the ten ADL items. Complete BI proﬁles from
246 stroke inpatients were entered into a database and seg-
mented by score. Data were validated against published ﬁndings.
For each score, the number of unique proﬁles and their fre-
quencies were calculated. The clinical and economic implications
of differences in proﬁles at the same score were assessed.
RESULTS: In total, 697 complete BI proﬁles were obtained from
patient data, of which 246 were unique. Excepting the scoring
extremes, the number of unique proﬁles at each BI score ranged
